BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arif A, Levine RA, Sanderson SO, Bank L, Velu RP, Shah A, Mahl TG, Gregory DH. Regression of fibrosis in chronichepatitis C after therapy with interferon and ribavirin. Dig Dis Sci. 2003;48:1425-1430. [PMID: 12870807 DOI: 10.1023/a:1024196201684] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504-1508. [PMID: 15361504 DOI: 10.1136/gut.2003.038257] [Cited by in Crossref: 119] [Cited by in F6Publishing: 112] [Article Influence: 6.6] [Reference Citation Analysis]
2 D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One 2016;11:e0155967. [PMID: 27304619 DOI: 10.1371/journal.pone.0155967] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
3 Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, Schmiegel W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. Clin Mol Hepatol 2019;25:42-51. [PMID: 30449076 DOI: 10.3350/cmh.2018.0029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
5 Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009;29:4-14. [PMID: 19139619 DOI: 10.4103/0256-4947.51816] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
6 D'Ambrosio R, Aghemo A. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 2012;12:361-8. [PMID: 22879824 DOI: 10.5812/hepatmon.6095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
8 Al Ashgar H, Khan MQ, Helmy A, Al Swat K, Al Shehri A, Al Kalbani A, Peedikayel M, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Al Fadda M. Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience. Saudi J Gastroenterol 2008;14:58-65. [PMID: 19568501 DOI: 10.4103/1319-3767.39619] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
9 Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856 [PMID: 28740596 DOI: 10.4254/wjh.v9.i19.850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Huang YH, Shi MN, Zheng WD, Zhang LJ, Chen ZX, Wang XZ. Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats. World J Gastroenterol 2006; 12(9): 1386-1391 [PMID: 16552806 DOI: 10.3748/wjg.v12.i9.1386] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
11 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(3): 367-370 [DOI: 10.11569/wcjd.v13.i3.367] [Reference Citation Analysis]
12 Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med. 2010;2010:125-145. [PMID: 21331152 DOI: 10.2147/hmer.s7193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
13 Tsui TY, Lau CK, Ma J, Glockzin G, Obed A, Schlitt HJ, Fan ST. Adeno-associated virus-mediated heme oxygenase-1 gene transfer suppresses the progression of micronodular cirrhosis in rats. World J Gastroenterol 2006; 12(13): 2016-2023 [PMID: 16610050 DOI: 10.3748/wjg.v12.i13.2016] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
14 Hines CD, Bley TA, Lindstrom MJ, Reeder SB. Repeatability of magnetic resonance elastography for quantification of hepatic stiffness. J Magn Reson Imaging. 2010;31:725-731. [PMID: 20187219 DOI: 10.1002/jmri.22066] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 9.0] [Reference Citation Analysis]